Compugen Stock Price, News & Analysis

Compugen Ltd. (Nasdaq: CGEN) has announced that it will present new clinical data regarding its candidate COM701 during the upcoming American Society of Clinical Oncology (ASCO) annual meeting from June 2-6, 2023, in Chicago. The data will focus on the triple combination therapy of COM701, BMS-986207 (anti-TIGIT), and nivolumab in patients with metastatic endometrial cancer. The presentation titled Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab is scheduled for June 5, 2023. This research highlights Compugen's commitment to innovative cancer immunotherapy methods.
Company Background: Compugen is advancing several therapeutic programs, including COM902 and the partnered program rilvegostomig, with a focus on addressing immune resistance in cancer treatments.

Compugen Ltd. (Nasdaq: CGEN) announced the upcoming presentation of pre-clinical data on its lead asset, COM503, at the 20th CIMT Annual Meeting in Mainz, Germany, from May 3-5, 2023. COM503 is a first-in-class anti-IL18 binding protein antibody designed to inhibit cancer growth by releasing endogenous IL-18, which is crucial for activating NK and T cells in the tumor microenvironment. The company's plan includes filing an IND for COM503 in 2024.

The presentation, featuring high-affinity interactions of COM503 with IL-18 binding protein, aims to demonstrate enhanced anti-tumor activity while preserving peripheral immunity. Compugen's research highlights the potential of targeting cytokine biology in cancer treatment and positions COM503 as a transformative candidate within its broader immuno-oncology pipeline.

Compugen Ltd. (NASDAQ: CGEN) announced its upcoming presentation at the AACR annual meeting from April 14-19, 2023, in Orlando, Florida. The research focuses on the correction of the GENCODE gene model, which enables accurate detection of the novel target PVRIG. This advancement aims to enhance cancer immunotherapy research. Dr. Anat Cohen-Dayag emphasized the importance of single cell technology in understanding cancer biology. The presentation is scheduled for April 18, 2023, and will explore algorithms for gene model correction impacting PVRIG and TIGIT pathways. Compugen is advancing its product candidates, COM701 and COM902, targeting solid tumors.

Compugen Ltd. (Nasdaq: CGEN) will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 AM ET. The event will be held virtually, and interested parties can access a live webcast through the Investor Relations section of Compugen's website. A replay will be available for 90 days post-event. Compugen is focused on developing cancer immunotherapies, with notable candidates including COM701 and COM902. The company is headquartered in Israel and also has a presence in San Francisco, CA.